|
Joining
forces
Prohibitively high costs of R&D has made the process of
drug discovery a commercial affair. Indian pharma companies
are exploring various collaborative strategies to reduce the
R&D burden. By Katya Naidu.
India
eyes the nutra pie
Ipsita Guha reports the Frost & Sullivan event on fortified
foods and supplements.
Upcoming
Events
'The
future is for preventive therapy'
GC Chemie Pharmie started off as a trading house and has come
a long way. It is now bracing itself to venture into the nutraceutical
segment. Gautam Shah, Managing Director talks to Sonal Shukla
about the company activities and future plans.
Q1
Results
Granules
India gets FDA nod
Granules India and Amneal Pharmaceutical (United States) announced
the approval of its ANDA of Metformin Hydrochloride tablets
of 500 milligram, 850 milligram and 1000 milligram. This is
the first time that USFDA has approved an ANDA with a Pharmaceutical
Formulation Intermediate (PFI)—DMF as a raw material.
Glenmark
gets USFDA nod to market generic Meloxicam
Glenmark received USFDA approval to market Meloxicam oral
tablets 7.5 milligram and 15 milligram, a generic version
of Boehringer Ingelheim's brand, Mobic.
Products
|
